西南证券发布美好医疗研报

Group 1 - The core business of Meihao Medical is currently under pressure due to tariff impacts, but improvements are expected in the second half of 2025 [2] - New business segments are entering a harvest phase, indicating a clearer second growth curve [2] - The implementation of equity incentives reflects confidence in the company's prospects, with both organic and external growth drivers in play [2]